Receiving Tomorrow's Treatments Today at Bethesda
When you're looking for the most advanced drug treatments available, turn to the clinical research experts at the Bethesda Research Center.
These clinical trials are listed for informational purposes, and are not to be used outside of a clinical trial setting. Please contact the Bethesda Research Center at (561) 374-5020 for full particulars regarding enrollment of any clinical trial.
CURRENTLY ENROLLING CLINICAL TRIALS
1. Cardiovascular Chronic Heart Failure
» Principal Investigator: George Daniel M.D.
- Study Title: A double-blind, randomized, Sham-procedure-controlled, parallel-group efficacy and safety study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in patients with chronic heart failure due to left ventricular systolic dysfunction of either ischemic or non-ischemic etiology.
- Study Summary: If you are between 18 to 80 years of age and currently suffering from chronic heart failure, you may be eligible to take part in a clinical research study called DREAM HF-1.
- Study Objective: The purpose of this study is to evaluate the efficacy and safety of a single cardiac catheterization involving transendocardial delivery of human bone marrow allogeneic (rexlemestrocel-L) in improving clinical outcomes, preventing cardiac remodeling, and increasing exercise capacity in patient with chronic HF due to LV systolic dysfunction of either ischemic or non-ischemic etiology who have received optimal medical/revascularization therapy.
2. Cardiovascular Disease:
» Principal Investigator: Rachel Eidelman, M.D.
- Study Title: A randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infraction (MI).
- Study Summary: If you are a diabetic male or female, 50 years of age or older with a history of an MI (heart attack), you may be eligible to take part in a clinical research study called TACT2.
- Study Objective: The primary objective of TACT2 to replicate the findings of TACT1, which found a striking reduction of recurrent cardiovascular events in post-MI diabetic patients receiving edetate disodium-based chelation therapy.
3. Cardiovascular Chronic Heart Failure:
» Principal Investigator: Yoel R. Vivas, M.D.
- Study Title: A multicenter trial to guide ICD implantation in heart failure patients.
- Study Summary: If your doctor is planning an ICD implantation you may qualify to take part in a study called Admire-ICD.
- Study Objective: The primary objective of this study is to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of ICD implantation in a population of New York Heart Association (NYHA) class II and III Heart Failure (HF) patients with 30% left ventricular ejection fraction (LVEF) 35%.
UPCOMING CLINICAL TRIALS
1. Cardiovascular Disease:
» Principal Investigator: George Daniel, M.D.
- Study Title: A prospective, multicenter, global randomized controlled trial assessing the safety and efficacy of the BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System in patients with stable coronary artery disease or non-ST segment elevation acute coronary syndromes.
- Study Summary: If you're a male or non-pregnant female over the age of 20 that has symptomatic ischemic heart disease, including chronic stable angina, have had a heart attack and or acute coronary syndromes that requires elective or urgent percutaneous coronary intervention (PCI), you may qualify to take part in this study called Pioneer.
- Study Objective: The primary objective of this study is to demonstrate the safety and efficacy of the BuMA DES in patients with functionally significant ischemia requiring percutaneous coronary intervention (PCI) with implantation of drug eluting stents for the treatment of stable coronary artery disease or acute coronary syndromes without ST-segment elevation by randomized comparison with commercially available durable polymer everolimus-eluting stent systems.
2. Infectious Disease:
» Principal Investigator: Carlos Miniet, M.D.
- Study Title: A phase 2b, randomized double-blind, single-dose, active-controlled, dose ranging study to evaluate the efficacy and safety of MEDI8852 in adults who are hospitalized with influenza caused by Type A strains.
- Study Summary: If you are 18 years of age or older and are currently being hospitalized with influenza caused by Type A strains, you may be a candidate for this study.
- Study Objective: The primary objective of this study is to evaluate the effect of MEDI8852 administered in conjunction with oseltamivir and the effect of oseltamivir alone in reducing time to normalization of respiratory function. Also to compare the safety and tolerability of a single intravenous (IV) dose of MEDI8852 administered in conjunction with oseltamivir to the safety and tolerability of oseltamivir alone.
The Bethesda Research Center is located at Bethesda Hospital East. For more information regarding our clinical trials, please call us at (561) 374-5020.